These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32681754)

  • 41. Diencephalic pediatric low-grade glioma harboring the BRAF V600E mutation presenting with various morphologies in sequential biopsy specimens.
    Ishi Y; Hatanaka KC; Yamaguchi S; Fujita H; Motegi H; Kobayashi H; Terasaka S; Houkin K
    Brain Tumor Pathol; 2017 Oct; 34(4):165-171. PubMed ID: 28836232
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PCV chemotherapy for recurrent glioblastoma multiforme.
    Boiardi A
    Neurology; 2001 Jun; 56(12):1782. PubMed ID: 11425963
    [No Abstract]   [Full Text] [Related]  

  • 43. Combination of BRAF and MEK inhibition in BRAF V600E mutant low-grade ganglioglioma.
    Yau WH; Ameratunga M
    J Clin Pharm Ther; 2020 Oct; 45(5):1172-1174. PubMed ID: 31985841
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas.
    Peyre M; Cartalat-Carel S; Meyronet D; Ricard D; Jouvet A; Pallud J; Mokhtari K; Guyotat J; Jouanneau E; Sunyach MP; Frappaz D; Honnorat J; Ducray F
    Neuro Oncol; 2010 Oct; 12(10):1078-82. PubMed ID: 20488959
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [BRAF V600E mutation and clinicopathologic characteristics in 250 cases of brain tumors associated with epilepsy].
    Qi XL; Yao K; Duan ZJ; Bian Y; Ma Z; Piao YS; Gong LP
    Zhonghua Bing Li Xue Za Zhi; 2018 Sep; 47(9):664-670. PubMed ID: 30220118
    [No Abstract]   [Full Text] [Related]  

  • 46. Salvage chemotherapy for recurrent primary brain tumors in children.
    van Eys J; Baram TZ; Cangir A; Bruner JM; Martinez-Prieto J
    J Pediatr; 1988 Sep; 113(3):601-6. PubMed ID: 3411410
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Low-grade oligodendroglioma responds to chemotherapy.
    Mason WP; Krol GS; DeAngelis LM
    Neurology; 1996 Jan; 46(1):203-7. PubMed ID: 8559376
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Aggressive oligodendroglioma: a chemosensitive tumor.
    Cairncross JG; Macdonald DR; Ramsay DA
    Neurosurgery; 1992 Jul; 31(1):78-82. PubMed ID: 1641113
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors.
    Levin VA; Edwards MS; Wright DC; Seager ML; Schimberg TP; Townsend JJ; Wilson CB
    Cancer Treat Rep; 1980; 64(2-3):237-44. PubMed ID: 7407756
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for temozolomide.
    Rinne ML; Wen PY
    Oncology (Williston Park); 2015 Apr; 29(4):265, 275. PubMed ID: 25952491
    [No Abstract]   [Full Text] [Related]  

  • 51. Chemotherapy of low-grade gliomas.
    Lesser GJ
    Semin Radiat Oncol; 2001 Apr; 11(2):138-44. PubMed ID: 11285551
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sarcoid-like reaction in a child following prolonged therapeutic exposure to dabrafenib and trametinib for BRAF V600E mutated hypothalamic/chiasmatic glioma.
    Wilhelmsson M; Chun FJ; Yeung RSM; Krtizinger F; McKeown T; Coblentz A; Ertl-Wagner B; Tabori U; Bartels U; Das A
    Pediatr Blood Cancer; 2023 Nov; 70(11):e30619. PubMed ID: 37555268
    [No Abstract]   [Full Text] [Related]  

  • 53. Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study.
    Soffietti R; Nobile M; Rudà R; Borgognone M; Costanza A; Laguzzi E; Mutani R
    Cancer; 2004 Feb; 100(4):807-13. PubMed ID: 14770438
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chemotherapy for diffuse low-grade gliomas in adults.
    Ducray F
    Rev Neurol (Paris); 2011 Oct; 167(10):673-9. PubMed ID: 21906770
    [TBL] [Abstract][Full Text] [Related]  

  • 55. cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF
    Ellison DW; Hawkins C; Jones DTW; Onar-Thomas A; Pfister SM; Reifenberger G; Louis DN
    Acta Neuropathol; 2019 Apr; 137(4):683-687. PubMed ID: 30848347
    [No Abstract]   [Full Text] [Related]  

  • 56. Response and control: lessons from oligodendroglioma.
    Cairncross JG; Eisenhauer EA
    J Clin Oncol; 1995 Sep; 13(9):2475-6. PubMed ID: 7666112
    [No Abstract]   [Full Text] [Related]  

  • 57. Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas.
    Triebels VH; Taphoorn MJ; Brandes AA; Menten J; Frenay M; Tosoni A; Kros JM; Stege EB; Enting RH; Allgeier A; van Heuvel I; van den Bent MJ
    Neurology; 2004 Sep; 63(5):904-6. PubMed ID: 15365146
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Medical Research Council adjuvant trial in high-grade gliomas.
    Chamberlain MC; Jaeckle KA
    J Clin Oncol; 2001 Oct; 19(19):3997-9. PubMed ID: 11579124
    [No Abstract]   [Full Text] [Related]  

  • 59. Advantage of post-radiotherapy chemotherapy with CCNU, procarbazine, and vincristine (mPCV) over chemotherapy with VM-26 and CCNU for malignant gliomas.
    Jeremic B; Jovanovic D; Djuric LJ; Jevremovic S; Mijatovic LJ
    J Chemother; 1992 Apr; 4(2):123-6. PubMed ID: 1321239
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Procarbazine, CCNU and vincristine (PCV) combination chemotherapy for brain tumors.
    Brufman G; Halpern J; Sulkes A; Catane R; Biran S
    Oncology; 1984; 41(4):239-41. PubMed ID: 6462602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.